Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I–III Clinical Trials

INTRODUCTION: We characterized the safety and tolerability of empagliflozin in patients with type 2 diabetes (T2DM) randomized 1:1:1 to placebo, empagliflozin 10 mg, or empagliflozin 25 mg in clinical trials. METHODS: Pooled data were analyzed from patients with T2DM treated with placebo (N = 4203),...

Descripción completa

Detalles Bibliográficos
Autores principales: Kohler, Sven, Zeller, Cordula, Iliev, Hristo, Kaspers, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504200/
https://www.ncbi.nlm.nih.gov/pubmed/28631216
http://dx.doi.org/10.1007/s12325-017-0573-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504200/
https://www.ncbi.nlm.nih.gov/pubmed/28631216
http://dx.doi.org/10.1007/s12325-017-0573-0

Ejemplares similares